ID

41001

Descrizione

Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.; ODM derived from: https://clinicaltrials.gov/show/NCT02072330

collegamento

https://clinicaltrials.gov/show/NCT02072330

Keywords

versioni (1)
  1. 10/06/20 10/06/20 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

10 giugno 2020

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Grade I or II Essential Hypertension NCT02072330

Inglese

Eligibility Grade I or II Essential Hypertension NCT02072330

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. grade i or ii essential hypertension.
Descrizione

Essential Hypertension Grade

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0085580
UMLS CUI [1,2]
C0441800
2. an office sitting systolic blood pressure of ≥ 150 and < 180 mmhg, and an office sitting diastolic blood pressure of ≥ 95 and < 110 mmhg during the placebo run-in period at week −2 and week 0.
Descrizione

Sitting systolic blood pressure | Sitting diastolic blood pressure

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1319893
UMLS CUI [2]
C1319894
3. male or female aged 20 years or older at the time of providing informed consent.
Descrizione

Age | Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0021430
4. outpatient.
Descrizione

Outpatient

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0029921
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. secondary hypertension, grade iii hypertension or malignant hypertension.
Descrizione

Secondary hypertension | Hypertensive disease Grade | Malignant Hypertension

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0155616
UMLS CUI [2,1]
C0020538
UMLS CUI [2,2]
C0441800
UMLS CUI [3]
C0020540
2. an office sitting systolic blood pressure of ≥160 mmhg or sitting diastolic blood pressure of ≥100 mmhg recorded while on combined therapy with 3 or more antihypertensives within 4 weeks prior to the initiation of the placebo run-in period and at week −4.
Descrizione

Sitting systolic blood pressure | Sitting diastolic blood pressure | Combined Modality Therapy | Antihypertensive Agents Quantity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1319893
UMLS CUI [2]
C1319894
UMLS CUI [3]
C0009429
UMLS CUI [4,1]
C0003364
UMLS CUI [4,2]
C1265611
3 evident white coat hypertension or white coat phenomenon. 4. day-night reversed lifestyle, such as night-time workers. 5. sleep apnea syndrome requiring treatment. 6. have any of the cardiovascular disease or symptoms listed below:
Descrizione

White Coat Hypertension | Other Coding | Night shift worker | Sleep Apnea Syndrome Treatment required for | Cardiovascular Disease | Cardiovascular symptoms

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0262534
UMLS CUI [2]
C3846158
UMLS CUI [3]
C0555008
UMLS CUI [4,1]
C0037315
UMLS CUI [4,2]
C0332121
UMLS CUI [5]
C0007222
UMLS CUI [6]
C0476270
heart disease: myocardial infarction (within 24 weeks before the placebo run-in period), coronary arterial revascularization (within 24 weeks before the placebo run-in period), severe valvular disease, atrial fibrillation, or following diseases which require medication: angina pectoris, congested heart failure, or arrhythmia.
Descrizione

Heart Disease | Myocardial Infarction | Coronary revascularisation | Valvular disease Severe | Atrial Fibrillation | Disease Requirement Pharmaceutical Preparations | Angina Pectoris | Congestive heart failure | Cardiac Arrhythmia

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0018799
UMLS CUI [2]
C0027051
UMLS CUI [3]
C0877341
UMLS CUI [4,1]
C3258293
UMLS CUI [4,2]
C0205082
UMLS CUI [5]
C0004238
UMLS CUI [6,1]
C0012634
UMLS CUI [6,2]
C1514873
UMLS CUI [6,3]
C0013227
UMLS CUI [7]
C0002962
UMLS CUI [8]
C0018802
UMLS CUI [9]
C0003811
cerebrovascular disease: cerebral infarction, cerebral hemorrhage (within 24 weeks before the placebo run-in period), or transient ischemic attack (within 24 weeks before the placebo run-in period).
Descrizione

Cerebrovascular Disorder | Cerebral Infarction | Cerebral Hemorrhage | Transient Ischemic Attack

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0007820
UMLS CUI [2]
C0007785
UMLS CUI [3]
C2937358
UMLS CUI [4]
C0007787
vascular diseases: peripheral arterial disease with intermittent claudication, artery dissection, aneurysm
Descrizione

Vascular Diseases | Peripheral Arterial Disease | Intermittent Claudication | Arterial dissection | Aneurysm

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0042373
UMLS CUI [2]
C1704436
UMLS CUI [3]
C0021775
UMLS CUI [4]
C0002949
UMLS CUI [5]
C0002940
advanced hypertensive retinopathy: bleeding, exudation, or papilledema (within 24 weeks before the placebo run-in period).
Descrizione

Hypertensive Retinopathy Advanced | Hemorrhage | Exudation | Papilledema

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0152132
UMLS CUI [1,2]
C0205179
UMLS CUI [2]
C0019080
UMLS CUI [3]
C0311437
UMLS CUI [4]
C0030353
7. clinically significant hepatic disorder. 8. clinically significant renal impairment. 9. significantly low or high potassium or sodium levels. 10. complicated by gout, or had a past history of gout within 24 weeks prior to the initiation of the placebo run-in period, or complicated by hyperuricemia requiring medication.
Descrizione

Liver disease | Renal Insufficiency | Potassium low | Potassium increased | Sodium decreased | Sodium high | Complication Due to Gout | Gout | Complication Due to Hyperuricemia | Pharmaceutical Preparations Required

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023895
UMLS CUI [2]
C1565489
UMLS CUI [3]
C0860866
UMLS CUI [4]
C0856882
UMLS CUI [5]
C0860871
UMLS CUI [6]
C0595879
UMLS CUI [7,1]
C0009566
UMLS CUI [7,2]
C0678226
UMLS CUI [7,3]
C0018099
UMLS CUI [8]
C0018099
UMLS CUI [9,1]
C0009566
UMLS CUI [9,2]
C0678226
UMLS CUI [9,3]
C0740394
UMLS CUI [10,1]
C0013227
UMLS CUI [10,2]
C1514873
11. diabetic subject on insulin treatment or poorly controlled type 2 diabetes mellitus.
Descrizione

Diabetic | Insulin regime | Type II diabetes mellitus uncontrolled

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0241863
UMLS CUI [2]
C0557978
UMLS CUI [3]
C2733146
12. have a malignant tumor.
Descrizione

Malignant Neoplasm

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
Ritorna all'inizio della pagina

Similar models

Eligibility Grade I or II Essential Hypertension NCT02072330

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Essential Hypertension Grade
Item
1. grade i or ii essential hypertension.
boolean
C0085580 (UMLS CUI [1,1])
C0441800 (UMLS CUI [1,2])
Sitting systolic blood pressure | Sitting diastolic blood pressure
Item
2. an office sitting systolic blood pressure of ≥ 150 and < 180 mmhg, and an office sitting diastolic blood pressure of ≥ 95 and < 110 mmhg during the placebo run-in period at week −2 and week 0.
boolean
C1319893 (UMLS CUI [1])
C1319894 (UMLS CUI [2])
Age | Informed Consent
Item
3. male or female aged 20 years or older at the time of providing informed consent.
boolean
C0001779 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
Outpatient
Item
4. outpatient.
boolean
C0029921 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Secondary hypertension | Hypertensive disease Grade | Malignant Hypertension
Item
1. secondary hypertension, grade iii hypertension or malignant hypertension.
boolean
C0155616 (UMLS CUI [1])
C0020538 (UMLS CUI [2,1])
C0441800 (UMLS CUI [2,2])
C0020540 (UMLS CUI [3])
Sitting systolic blood pressure | Sitting diastolic blood pressure | Combined Modality Therapy | Antihypertensive Agents Quantity
Item
2. an office sitting systolic blood pressure of ≥160 mmhg or sitting diastolic blood pressure of ≥100 mmhg recorded while on combined therapy with 3 or more antihypertensives within 4 weeks prior to the initiation of the placebo run-in period and at week −4.
boolean
C1319893 (UMLS CUI [1])
C1319894 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
C0003364 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
White Coat Hypertension | Other Coding | Night shift worker | Sleep Apnea Syndrome Treatment required for | Cardiovascular Disease | Cardiovascular symptoms
Item
3 evident white coat hypertension or white coat phenomenon. 4. day-night reversed lifestyle, such as night-time workers. 5. sleep apnea syndrome requiring treatment. 6. have any of the cardiovascular disease or symptoms listed below:
boolean
C0262534 (UMLS CUI [1])
C3846158 (UMLS CUI [2])
C0555008 (UMLS CUI [3])
C0037315 (UMLS CUI [4,1])
C0332121 (UMLS CUI [4,2])
C0007222 (UMLS CUI [5])
C0476270 (UMLS CUI [6])
Heart Disease | Myocardial Infarction | Coronary revascularisation | Valvular disease Severe | Atrial Fibrillation | Disease Requirement Pharmaceutical Preparations | Angina Pectoris | Congestive heart failure | Cardiac Arrhythmia
Item
heart disease: myocardial infarction (within 24 weeks before the placebo run-in period), coronary arterial revascularization (within 24 weeks before the placebo run-in period), severe valvular disease, atrial fibrillation, or following diseases which require medication: angina pectoris, congested heart failure, or arrhythmia.
boolean
C0018799 (UMLS CUI [1])
C0027051 (UMLS CUI [2])
C0877341 (UMLS CUI [3])
C3258293 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
C0004238 (UMLS CUI [5])
C0012634 (UMLS CUI [6,1])
C1514873 (UMLS CUI [6,2])
C0013227 (UMLS CUI [6,3])
C0002962 (UMLS CUI [7])
C0018802 (UMLS CUI [8])
C0003811 (UMLS CUI [9])
Cerebrovascular Disorder | Cerebral Infarction | Cerebral Hemorrhage | Transient Ischemic Attack
Item
cerebrovascular disease: cerebral infarction, cerebral hemorrhage (within 24 weeks before the placebo run-in period), or transient ischemic attack (within 24 weeks before the placebo run-in period).
boolean
C0007820 (UMLS CUI [1])
C0007785 (UMLS CUI [2])
C2937358 (UMLS CUI [3])
C0007787 (UMLS CUI [4])
Vascular Diseases | Peripheral Arterial Disease | Intermittent Claudication | Arterial dissection | Aneurysm
Item
vascular diseases: peripheral arterial disease with intermittent claudication, artery dissection, aneurysm
boolean
C0042373 (UMLS CUI [1])
C1704436 (UMLS CUI [2])
C0021775 (UMLS CUI [3])
C0002949 (UMLS CUI [4])
C0002940 (UMLS CUI [5])
Hypertensive Retinopathy Advanced | Hemorrhage | Exudation | Papilledema
Item
advanced hypertensive retinopathy: bleeding, exudation, or papilledema (within 24 weeks before the placebo run-in period).
boolean
C0152132 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0019080 (UMLS CUI [2])
C0311437 (UMLS CUI [3])
C0030353 (UMLS CUI [4])
Liver disease | Renal Insufficiency | Potassium low | Potassium increased | Sodium decreased | Sodium high | Complication Due to Gout | Gout | Complication Due to Hyperuricemia | Pharmaceutical Preparations Required
Item
7. clinically significant hepatic disorder. 8. clinically significant renal impairment. 9. significantly low or high potassium or sodium levels. 10. complicated by gout, or had a past history of gout within 24 weeks prior to the initiation of the placebo run-in period, or complicated by hyperuricemia requiring medication.
boolean
C0023895 (UMLS CUI [1])
C1565489 (UMLS CUI [2])
C0860866 (UMLS CUI [3])
C0856882 (UMLS CUI [4])
C0860871 (UMLS CUI [5])
C0595879 (UMLS CUI [6])
C0009566 (UMLS CUI [7,1])
C0678226 (UMLS CUI [7,2])
C0018099 (UMLS CUI [7,3])
C0018099 (UMLS CUI [8])
C0009566 (UMLS CUI [9,1])
C0678226 (UMLS CUI [9,2])
C0740394 (UMLS CUI [9,3])
C0013227 (UMLS CUI [10,1])
C1514873 (UMLS CUI [10,2])
Diabetic | Insulin regime | Type II diabetes mellitus uncontrolled
Item
11. diabetic subject on insulin treatment or poorly controlled type 2 diabetes mellitus.
boolean
C0241863 (UMLS CUI [1])
C0557978 (UMLS CUI [2])
C2733146 (UMLS CUI [3])
Malignant Neoplasm
Item
12. have a malignant tumor.
boolean
C0006826 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial